Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LESTAURTINIB for B precursor type acute leukaemia: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 5 adverse event reports in the FDA FAERS database where LESTAURTINIB was used for B precursor type acute leukaemia.

Most Reported Side Effects for LESTAURTINIB

Side Effect Reports % Deaths Hosp.
Febrile neutropenia 23 28.8% 0 23
Hypertriglyceridaemia 13 16.3% 10 5
Clostridium difficile colitis 10 12.5% 0 10
Death 10 12.5% 10 5
Diarrhoea 10 12.5% 0 10
Enterococcal infection 9 11.3% 0 9
Sepsis 9 11.3% 0 9
Bronchiolitis 8 10.0% 0 8
Candida infection 8 10.0% 0 8
Hypertension 8 10.0% 0 8
Klebsiella infection 8 10.0% 0 8
Otitis externa 8 10.0% 0 8
Pulmonary oedema 8 10.0% 0 8
Septic shock 8 10.0% 0 8
Vomiting 8 10.0% 0 8

Other Indications for LESTAURTINIB

Acute lymphocytic leukaemia (64)

Other Drugs Used for B precursor type acute leukaemia

BLINATUMOMAB (1,791) METHOTREXATE (1,067) VINCRISTINE (977) DEXAMETHASONE (662) CYTARABINE (644) CYCLOPHOSPHAMIDE (598) PEGASPARGASE (531) MERCAPTOPURINE (484) DOXORUBICIN (331) DAUNORUBICIN (274)

Related Pages

LESTAURTINIB Full Profile All B precursor type acute leukaemia Drugs LESTAURTINIB Demographics LESTAURTINIB Timeline